Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease

Summary

One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by diabetes and obesity, and is becoming more common. Although many people have this disease, the change in how the liver handles drugs and compounds in the body has not been studied. The purpose of this study is to investigate how advanced NAFLD changes the ability of the liver to handle both endogenous and exogenous compounds.

Timeline

Start

2012-11

Primary completion

2014-03

Completion

2014-06

Drugs

Indications